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Background: Inhaled carbon monoxide (CO) appears to have beneficial effects on endotoxemia-induced impairment
of hypoxic pulmonary vasoconstriction (HPV). This study aims to specify correct timing of CO application, it’s
biochemical mechanisms and effects on inflammatory reactions.
Methods: Mice (C57BL/6; n = 86) received lipopolysaccharide (LPS, 30 mg/kg) intraperitoneally and subsequently
breathed 50 ppm CO continuously during defined intervals of 3, 6, 12 or 18 h. Two control groups received saline
intraperitoneally and additionally either air or CO, and one control group received LPS but breathed air only. In an
isolated lung perfusion model vasoconstrictor response to hypoxia (FiO2 = 0.01) was quantified by measurements of
pulmonary artery pressure. Pulmonary capillary pressure was estimated by double occlusion technique. Further,
inflammatory plasma cytokines and lung tissue mRNA of nitric-oxide-synthase-2 (NOS-2) and heme oxygenase-1
(HO-1) were measured.
Results: HPV was impaired after LPS-challenge (p < 0.01). CO exposure restored HPV-responsiveness if administered
continuously for full 18 h, for the first 6 h and if given in the interval between the 3rd and 6th hour after LPS-challenge
(p < 0.05). Preserved HPV was attributable to recovered arterial resistance and associated with significant reduction in
NOS-2 mRNA when compared to controls (p < 0.05). We found no effects on inflammatory plasma cytokines.
Conclusion: Low-dose CO prevented LPS-induced impairment of HPV in a time-dependent manner, associated with a
decreased NOS-2 expression.
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Hypoxic pulmonary vasoconstriction (HPV) represents
the main physiological mechanism to match ventilation
to perfusion in the lungs and is crucial for appropriate
systemic oxygenation [1, 2]. However, loss of HPV dur-
ing inflammatory conditions, e.g. sepsis, may lead to
intrapulmonary shunting of venous blood and severe
hypoxemia [3–5]. The impairment of HPV represents
an important pathophysiological factor during the de-
velopment of sepsis-induced lung injury. Thus, the* Correspondence: thilo.busch@medizin.uni-leipzig.de
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sent a potential therapeutic option to reduce its still
high mortality of 30–50 % [6–9].
So far, the mechanism of impairment of HPV during
sepsis remains elusive[10]. Experimental endotoxemia
impairs HPV in several animal models, with increased
production of cytokines and nitric oxide (NO) by the
inducible nitric-oxide-synthase 2 (NOS-2) being respon-
sible for loss of HPV [5, 11–15]. Preservation of HPV
during experimental sepsis was achieved by administra-
tion of reactive oxygen species scavengers, by inhibition
of NOS-2 with subsequent NO production or inhibition
of the soluble guanylate cyclase as a molecular target of
NO [5, 11, 15, 16].distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Jahn et al. Respiratory Research  (2015) 16:119 Page 2 of 12Recently, carbon monoxide (CO) has been shown to
be highly beneficial during acute lung injury due to its
anti-inflammatory, anti-apoptotic and anti-proliferative
properties [17–20]. Inhalation of low-dose CO reduced
mortality and inflammatory response in various animal
models of acute lung injury [17, 19, 21]. Moreover, re-
cent clinical studies show a positive correlation between
survival rates and endogenously produced CO levels in
critically ill patients [22–24]. This marks CO as an intri-
guing therapeutic agent during acute inflammatory con-
ditions, as it can easily be administered by inhalation
[25–29]. In a previous study we could show that con-
tinuous inhalation of CO for more than 20 h improved
HPV during murine endotoxemia in a dose dependent
manner [30]. In the study presented we hypothesized
that timing of CO inhalation is critical for sustaining
HPV during endotoxemia and that the beneficial CO ef-
fects may be associated with a decrease in lung NOS-2
or HO-1 up-regulation or serum cytokine concentration.
Material & Methods
All animal experiments were approved by the Govern-
mental Animal Care Committee of the VU University
medical centre, Amsterdam, the Netherlands and were
conducted in conformity with “Guiding Principles in
the Care and Use of Vertebrate Animals in Research
and Training” and in accordance with the NIH guide-
lines for ethical animal research (Guide for the Care
and Use of Laboratory Animals, NIH-publication No.
85–23, revised 1996). A total of 86 adult male mice
with a body weight (bw) of 22.9 ± 0.2 g at the age of 8–12
weeks (C57BL/6; Harlan Laboratory, the Netherlands)
were studied.
Experimental groups
Mice were randomly assigned to eight groups of control
and endotoxemic animals. For induction of endotoxe-
mia, mice received an intraperitoneal (i.p.) injection of
30 mg/kg bw lipopolysaccharide (LPS; Escherichia coli
0111:B4 LPS, Sigma Aldrich Chemie GmbH, Steinheim,
Germany) dissolved in normal saline. Controls received
an equal amount of saline. After injection, animals were
placed in a ventilated chamber and exposed to 50 ppm
CO provided as a fixed gas mixture containing 50 ppm
CO in 21 % oxygen and balanced nitrogen (Linde Gas
Therapeutics Benelux B.V., Dieren, the Netherlands)
either continuously for 18 h or during defined intervals for
different groups. Controls were exposed to an adequate air
mixture without CO. Configuration of experimental groups
are given in Fig. 1.
Isolated perfused mouse lung model
Mice (n = 70) received a lethal injection of pentobar-
bital sodium intraperitoneal (300 mg/kg bw, Ceva SanteAnimale, Naaldwijk, the Netherlands) and were placed
in a 37 °C water-jacketed chamber (Isolated Perfused
Lung Size 1 type 839, Hugo- Sachs Elektronik, March-
Hugstetten, Germany). After tracheotomy, volume-
controlled ventilation (MiniVent type 845; Hugo-Sachs
Elektronik, March-Hugstetten, Germany) was initiated
with a tidal volume of 9 ml/kg bw, a positive end-
expiratory pressure of 2 cm H2O and a respiratory rate
of 100 breaths/min using a normoxic (FiO2 = 0.21) gas
mixture (21 % O2, 5 % CO2,, balanced N2, Linde Gas
Therapeutics Benelux B.V., Dieren, the Netherlands). After
median sternotomy, the right ventricle was punctured for
collection of a blood sample for cytokine measurements
and subsequent injection of 10 U heparin, followed by ex-
sanguination. For perfusion, cannulas (stainless steel, in-
ternal diameter 1 mm; Isolated Perfused Lung Size 1 type
839) were inserted into the pulmonary artery via the right
ventricle and into the left atrium via the left ventricle.
Lungs were perfused with a modified “Hanks’ balanced salt
solution” (Merck, KGaA, Darmstadt, Germany) containing
the following salts: 136.89 mmol/l NaCl, 5.37 mmol/l KCl,
0.34 mmol/l Na2HPO4, 0.44 mmol/l KH2PO4, 1.26 mmol/l
CaCl2, 0.81 mmol/l MgSO4, 5.56 mmol/l D-Glucose,
4.17 mmol/l NaHCO3. Bovine serum albumin (3 %, Sigma-
Aldrich Chemie GmbH, Steinheim, Germany) and dextran
(3 %, Sigma-Aldrich Chemie GmbH, Steinheim, Germany)
were added to the perfusate to prevent pulmonary edema
[15, 31, 32]. Indomethacin (30 mmol/l, Sigma-Aldrich
Chemie GmbH, Steinheim, Germany) and the non-
selective nitric oxide synthase inhibitor L-NAME (1 mmol/
l, Nω-Nitro-l-Argininmethylester; Sigma-Aldrich Chemie
GmbH, Steinheim, Germany) were added to the perfusate
to inhibit endogenous prostaglandin and NO synthesis,
respectively [15, 31, 32]. Sodium bicarbonate (B. Braun
Melsungen AG, Melsungen, Germany) was added to adjust
the perfusate pH between 7.34–7.45. Perfusion was realized
with a roller pump (ISM834A, IsmatecSA, Labortechnik-
Analytik, Glattbrugg-Zürich, Switzerland) at 50 ml⋅kg−1⋅
min−1 with a non-recirculating system at 37 °C, maintaining
left atrial pressure (LAP) at 2 mmHg. Perfusate flow (Q)
was adjusted using an in-line flow probe and flowmeter
(T402, Transonic-Systems Inc., Ithaca, New York, USA).
Pulmonary artery pressure (PAP) and LAP were measured
via saline-filled pressure transducers (Medex Medical
GmbH & Co KG, Klein-Winterheim, Germany) and a
transbridge amplifier (TBM4M; World Precision In-
struments, Berlin, Germany), and PAP, LAP, and Q
were recorded at 150 Hz per channel on a personal
computer using a data acquisition system (WinDaq™,
DATAQ Instruments, Akron, OH, USA).
Quantification of HPV
For quantification of HPV, we evaluated the hypoxia in-
duced increase in pulmonary artery pressure, measured
Fig. 1 Experimental groups; Saline = controls were treated with saline i.p; LPS =mice were treated with 30 mg/kg bw Escherichia coli lipopolysaccharide
i.p.; air (□) =mice were exposed to air; CO (■) =mice were exposed to 50 ppm CO; IPL = isolated perfused lung; ↓= time points of tissue sampling in the
molecular biology groups; * = collection of blood sample for cytokine detection; n = 8 per group
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32]. Initially, lungs were ventilated with the normoxic
gas mixture for 5 min and perfused at a constant flow
rate of 50 ml⋅kg−1⋅min−1 (baseline perfusion), while
maintaining a stable LAP value of 2 mmHg. Afterwards,
lungs received a hypoxic gas mixture (FiO2 = 0.01; 1 %
O2, 5 % CO2 and 94 % N2; Linde Gas Therapeutics
Benelux B.V., Dieren, the Netherlands). PAP was mea-
sured again after reaching a steady-state (approximately
10 to 15 min after initiation of hypoxic ventilation).
HPV response was defined as increase of PAP in percent
of baseline PAP during normoxic ventilation [15, 31, 32].
Quantification of pulmonary capillary pressure
Pulmonary capillary pressure was estimated by the
double occlusion technique (DBO) to evaluate the re-
sistance in the pulmonary circulation [33, 34]. This
technique is done as follows: after turning off the res-
pirator in expiration, inflow and outflow through the
lungs were stopped simultaneously for 5 s using two
electromagnetic micro-valves (Clippard Minimatic, Cin-
cinnati, OH). PAP and LAP were allowed to equilibrateand the resulting pressure represents the pressure in
the pulmonary capillaries (PCP) [33] (see Fig. 2). Dur-
ing constant flow perfusion, total pulmonary vascular
resistance is represented by the pressure drop across
the pulmonary vasculature, expressed as the difference
between PAP and LAP. Thus, the contribution of the
pre-capillary, arterial part of pulmonary vasculature to
total pulmonary vascular resistance can be expressed
as PAP reduced by PCP and accordingly, the contri-
bution of the post-capillary, venous part as PCP minus
LAP. DBO values were included when a stable PCP curve
was registered with complete equilibration of PAP and
LAP (80 % inclusion).
We applied this technique during normoxic and hyp-
oxic ventilation.
Cytokine measurements
Serum cytokine concentrations of IL-1β, IL-2, IL-4, IL-5,
IL-6, IL-10, IL-12, IL-13, TNFα, INFγ, GM-CSF and
MCP-1 were measured in four randomly chosen animals
from each the following groups: (saline/air 18 h), (LPS/
air 18 h), (saline/CO 18 h) and (LPS/CO 18 h).
Fig. 2 Double occlusion; Original recording of two successive double occlusion maneuvers (↓) during normoxic (21 % O2) and hypoxic (1 % O2)
ventilation in an isolated perfused mouse lung. PAP = pulmonary artery pressure, LAP = left atrial pressure, PCP = pulmonary capillary pressure.
Note that hypoxic ventilation predominantly causes arterial rather than venous vasoconstriction. *denotes interruption of ventilation
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profiling) technology with a pre mixed multiplex cyto-
kine assay (Milliplex Mouse Cytokine Premixed 12
Plex Immunoassay Kit, Millipore B.V., Amsterdam,
the Netherlands) and an automated Bio-plexTM 200
system (Cat# 171-000001FS1, Bio-Rad Laboratories
B.V., Veenendaal, the Netherlands) with data-detection
using the attendant software (Bio-plex Manager TM Soft-
ware 4.1, Bio-Rad Laboratories B.V., Veenendaal, the
Netherlands).
Molecular biology
For determination of LPS- and CO-induced changes in
mRNA expression, HO-1, HO-2 and NOS-2 were mea-
sured in the following groups: (saline/air18h), (LPS/air
18 h), (saline/CO 18 h) and (LPS/CO 18 h). In these
animals, lungs were perfused with iced physiological
saline for one minute at 50 ml⋅kg−1⋅min−1 flow (see iso-
lated lung protocol for details) and subsequently har-
vested for further analysis. RNA was isolated from
mouse lungs using Trizol reagent (Invitrogen Life
Technologies, Carlsbad, CA), and complementary DNA
was generated with iScript cDNA Synthesis Kit (BioRad
Laboratories, Richmond, CA). Quantitative reverse-
transcriptase PCR was performed with the ABI Prism
7000 Sequence Detection System (Applied Biosystems,





18S (TCAAGAACGAAAGTCGGAGG, GGACAT CTAA
GGGCATCAC)) and SYBR® Green PCR Master Mix
(Applied Biosystems, Foster City, CA). Postamplification
dissociation curves were performed to verify the presenceof a single amplification product in the absence of DNA
contamination. Changes in expression of the gene of
interest were determined using the Ct-method with
normalization to 18S ribosomal RNA.Statistical analysis
All values are expressed as means ± standard deviation
(SD). To compare differences between experimental
groups one-way or two-way ANOVA was performed
where appropriate. When significant differences were
detected, Bonferroni post hoc least significant difference
test for planned comparisons was used. All calculation
were performed with GraphPad Prism 5 (GraphPad Prism
5, La Jolla, CA).Results
General response to LPS and CO
18 h after LPS-challenge mice showed lethargy, piloerec-
tion and diarrhoea with no visible CO effects on general
appearance.Pulmonary vascular pressure during normoxia
Baseline pulmonary artery pressure (PAP) during
normoxic ventilation (FiO2 = 0.21) did not differ be-
tween LPS- and saline-treated animals. CO exposure
for 18 h did not affect baseline PAP during normoxia
in LPS- or saline-treated animals (see Fig. 3a). Base-
line PAP was not altered by CO, independently of
time and duration of CO exposure (see Fig. 3b). Dur-
ing baseline perfusion no significant LPS- or CO-
induced changes in arterial or venous fraction of
total pulmonary vascular resistance were detected
(see Fig. 4a and b).
Fig. 3 Baseline pulmonary artery pressure during normoxic ventilation; a. Average values of baseline pulmonary artery pressure (= PAP) during
ventilation with 21 % O2 in lungs obtained from saline-treated controls (open bars) and from lipopolysaccharide-treated mice (LPS, black bars)
after exposure to air or to 50 ppm CO for 18 h. Baseline PAP during nomoxic ventilation was not altered by LPS treatment or CO exposure.
b. Average values of baseline PAP in lungs obtained from LPS-treated mice after exposure to 50 ppm CO for the first 6 h, the last 12 h, the first
3 h and the second 3 h after LPS challenge. Baseline PAP in LPS-treated animals was not affected by CO, independently of time and duration of
CO exposure compared to CO exposure for 18 h. For better comparability values for the group (LPS/CO 18 h) are also depicted in figure B. Data
are presented in mmHg as mean ± SD; n = 8 per group
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Hypoxic ventilation (FiO2 = 0.01) increased PAP in
lungs of controls (saline/air 18 h) from 7.5 ± 1.2 to
15.2 ± 3.4 mmHg (p < 0.01). In LPS-treated animals
PAP was significantly lower during hypoxic ventilation
compared to saline-treated controls (p < 0.01). LPS-Fig. 4 Arterial and venous fraction of pulmonary vascular resistance during
= pulmonary artery pressure - pulmonary capillary pressure) during normox
(open bars) and from LPS-treated mice (black bars) after exposure to air or
resistance during normoxic ventilation were found. b. Average values of ve
pressure, with LAP = 2 mmHg) during normoxic ventilation in lungs obtain
(black bars) after exposure to air or to 50 ppm CO for 18 h. No CO- or LPS-
were found. Data are presented in mmHg as mean ± SD; n = 6–8 per grouptreatment (LPS/air 18 h) resulted in a significant re-
duction of HPV response (see Fig. 5a). HPV response
was attributable to a concomitant increase in arterial frac-
tion of total pulmonary vascular resistance in both saline-
and LPS-treated animals, respectively. The LPS-induced
impairment of HPV was attributable to a reduction ofnormoxic ventilation; a. Average values of arterial resistance (PAP-PCP
ic ventilation (21%O2) in lungs obtained from saline-treated controls
to 50 ppm CO for 18 h. No CO- or LPS-induced alterations in arterial
nous resistance (PCP-LAP = pulmonary capillary pressure - left atrial
ed from saline-treated controls (open bars) and from LPS-treated mice
induced alterations in venous resistance during normoxic ventilation
Fig. 5 Hypoxic pulmonary vasoconstriction expressed as increase of pulmonary artery pressure during hypoxic ventilation; a. Average values of
hypoxia induced vasoconstriction expressed as increase of pulmonary artery pressure (ΔPAP) in percent of baseline PAP in lungs obtained from
saline-treated controls (open bars) and from LPS-treated mice (black bars) after exposure to air or to 50 ppm CO for 18 h. Hypoxia induced
vasoconstriction was decreased in LPS-treated mice, which was prevented by exposure to 50 ppm CO for 18 h. b. Average values of ΔPAP in
lungs obtained from LPS-treated mice after exposure to 50 ppm CO for the first 6 h, the last 12 h, the first 3 h and the second 3 h after LPS
challenge. LPS-induced impairment of hypoxic pulmonary vasoconstriction was prevented by CO exposure for the first 6 h and the second
3 h after LPS challenge, but not by CO exposure for the first 3 h or the last 12 h. For better comparability values for the group (LPS/CO 18 h)
are also depicted in figure B. Data are presented as mean ± SD; n = 8 per group; *p < 0.01 vs. (saline/air 18 h); # p < 0.05 vs. (LPS/CO 18 h)
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(p < 0.05 versus controls) with no changes in venous
fraction see Fig. 6a and b).
Effect of CO exposure (18 h) on HPV responsiveness
While CO had no effect on HPV in saline-treated
animals with a hypoxia-induced increase in PAP fromFig. 6 Pressure differences determining arterial and venous fractions of pu
representing the arterial resistance (PAP-PCP = pulmonary artery pressure - pulm
obtained from saline-treated controls (open bars) and from LPS-treated mice (b
during hypoxia was decreased in LPS-treated mice, which was prevented by e
resistance (PCP-LAP = pulmonary capillary pressure - left atrial pressure,
from saline-treated controls (open bars) and from LPS-treated mice (black bar
alterations in venous resistance during hypoxic ventilation were found. Data a
18 h); # < 0.05 vs. (LPS/CO 18 h)7.2 ± 1.2 to 14.1 ± 2.0 mmHg, LPS-treated animals ex-
posed to CO for 18 h had a significantly higher HPV
with a hypoxia-induced increase in PAP from 7.9 ± 1.2
to 14.7 ± 3.1 mmHg (p < 0.05 versus (LPS/air 18 h);
see Fig. 5a). There was no detectable difference in
HPV of controls (saline/air 18 h) and LPS-treated an-
imals, exposed to CO for 18 h. Accordingly, the LPS-lmonary vascular resistance during hypoxic ventilation; a. Pressure drop
onary capillary pressure) during hypoxic ventilation (1%O2) in lungs
lack bars) after exposure to air or to 50 ppm CO for 18 h. Arterial resistance
xposure to 50 ppm CO for 18 h. b. Pressure drop representing the venous
with LAP = 2 mmHg) during hypoxic ventilation in lungs obtained
s) after exposure to air or to 50 ppm CO for 18 h. No CO- or LPS-induced
re presented as mean ± SD; n = 6–8 per group; *p < 0.05 vs. (saline/air
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ary vascular resistance during hypoxic ventilation,
which accounted for the impairment of HPV, was not
detectable in LPS-treated animals exposed to CO.
LPS-treated animals exposed to CO for 18 h had a
significantly higher arterial fraction of total pulmonary
vascular resistance during hypoxic ventilation com-
pared to LPS-treated animals without CO exposure
(p < 0.05 vs. (LPS/air 18 h). Following CO exposure,
the arterial fraction of total pulmonary vascular resistance
in LPS-treated animals was similar to that observed in
saline-treated animals with no CO dependent changes in
venous fraction (see Fig. 6a and b).
Time-dependence of CO exposure
CO exposure for the first 6 h after LPS injection (LPS/
CO 1st 6 h) followed by 12 h air exposure lead to a
significant increase of HPV response, with a hypoxia-
induced increase in PAP from 8.1 ± 0.7 to 15.5 ± 1.9 mmHg
with no detectable difference in HPV between 18 h and
6 h CO exposure. Yet, CO exposure starting 6 h after LPS
injection (LPS/CO last 12 h) resulted in a significantly
lower HPV compared to 18 h CO exposure (p < 0.05 ver-
sus (LPS/CO 18 h); see Fig. 5b). Hereby, PAP increased
from 8.1 ± 1.0 to 11.4 ± 2.4 mmHg during hypoxic
ventilation. CO exposure for the first 3 h after LPS
injection (LPS/CO 1st 3 h) resulted in no improve-
ment of HPV with a significantly lower ΔPAP com-
pared to 18 h CO (p < 0.05) with a hypoxia-induced
increase in PAP from 8.3 ± 1.0 to 12.2 ± 2.7 mmHg.
However, CO exposure for the second 3 h after LPS
injection (LPS/CO 2nd 3 h) did lead to a significant
elevation in HPV after LPS-challenge with a hypoxia-
induced increase in PAP from 7.3 ± 0.7 to 13.4 ± 1.4 mmHg
with no detectable difference in HPV between COTable 1 Serum concentration of cytokines (in pg/ml) 18 h after LPS
Cytokines (saline/air 18 h) (LPS/air 18 h)
IL-1β 6.7 ± 6.1(3) 923 ± 512
IL-2 (0) 21.1 ± 7.6
IL-4 0.9 ± 0.3(2) 9.4 ± 3.5
IL-5 10.4(1) 415 ± 140
IL-6 45.6 ± 4.0(2) 1,041,394 ± 1,305
IL-10 2.2 (1) 1744 ± 1074
IL-12 14.0 ± 9.2 1787 ± 485
IL-13 27.8 ± 7.2(2) 987 ± 518
TNF-α (0) 269 ± 106
INF-γ (0) 3039 ± 1819
GM-CSF (0) 338 ± 77,9
MCP-1 17.4 ± 23.1(2) 122,499 ± 96,48
Data are presented as mean ± SD; n = 4 per group; (n) = number of values within the
detectable concentrationtreatment for the entire 18 h period, the first 6 h or the
second 3 h (see Fig. 5b).
Cytokine serum concentrations
All measured serum cytokine levels were increased
after LPS treatment. However, there was no detectable
CO effect on serum cytokine concentrations in this two
groups (LPS/air 18 h vs. LPS/CO 18 h) (see Table 1).
Molecular biology
18 h after LPS injection and inhalation of air only, ani-
mals showed an increase of NOS-2 mRNA of 54-fold
compared to saline controls (p < 0.001). Exposure to CO
for 18 h did not affect NOS-2 expression in lungs of
saline-treated mice. However, the tissue levels of NOS-2
mRNA in LPS treated mice having received CO was
significantly reduced compared to LPS treated animals
without CO exposure (p < 0.05; see Fig. 7a). HO-1
mRNA was significantly increased 7-fold in LPS treated
animals 18 h after LPS-injection and inhalation of air
(p < 0.05 versus controls). After exposure to 50 ppm
CO for 18 h there was no significant difference in
HO-1 mRNA concentration between LPS- and saline-
treated animals. However, no significant difference
between LPS treated animals exposed to air or to CO
could be found either (see Fig. 7b). HO-2 mRNA
expression was not influenced by LPS treatment or
CO exposure (see Fig. 7c).
Discussion
The main finding of the present study is that exposure
to 50 ppm CO preserved hypoxic pulmonary vasocon-
striction in endotoxemic mice, when administered dur-
ing a short period in an early phase of endotoxemia.
Preserved HPV was associated with recovered arterial-challenge
(saline/CO 18 h) (LPS/CO 18 h)
19.8 ± 8.6(2) 761 ± 302
(0) 24.7 ± 7.9
(0) 9.8 ± 4.0
8.3 ± 5.9(3) 449 ± 300
,421 5.2(1) 438,575 ± 120,555
6.2 ± 5.7(2) 748 ± 281
33.1 ± 19.0(2) 1948 ± 383
30.3 ± 15.2 917 ± 281
(0) 246 ± 64.8
(0) 10,039 ± 10,856
32.8(1) 312 ± 50.7
8 (0) 80,492 ± 29,767
detectable concentration range if n ≠ 4; (0) = all values were below the least
Fig. 7 Increase of lung mRNA of NOS-2, HO-1 and HO-2 after LPS challenge; a. Average values of increase of NOS-2 mRNA in lungs from saline
treated controls (open bars) and LPS-treated mice (black bars) after exposure to air or to 50 ppm CO for 18 h. NOS-2 mRNA was increased in LPS-treated
mice more than 50fold compared to controls, which was prevented by exposure to 50 ppm CO for 18 h; *p< 0.001 vs. (saline/air 18 h); # p< 0.05 vs.
(LPS/CO 18 h). b. Average values of increase of HO-1 mRNA in lungs from saline treated controls (open bars) and LPS-treated mice (black bars) after
exposure to air or to 50 ppm CO for 18 h. HO-1 mRNA was increased in LPS-treated mice compared to controls, which was prevented by exposure to
50 ppm CO for 18 h; *p < 0.05 vs. (saline/air 18 h). c. Average values of increase of HO-2 mRNA in lungs from saline treated controls
(open bars) and LPS-treated mice (black bars) after exposure to air or to 50 ppm CO for 18 h. HO-2 mRNA was not increased in LPS-treated mice compared
to controls, which was not altered by exposure to 50 ppm CO for 18 h. Data are presented as mean ± SD
Jahn et al. Respiratory Research  (2015) 16:119 Page 8 of 12resistance and accompanied by a reduction in lung
NOS-2 mRNA expression.
We used an isolated perfused lung model to study the
response of pulmonary vasculature to alveolar hypoxia
in LPS-challenged mice. Administration of LPS induces
endotoxemia, which impairs HPV in several animal
models, including rodents, similar to loss of HPV during
sepsis in critically ill patients [11, 12, 14, 15]. Therefore,
LPS injection represents a highly reproducible and
clinically relevant model of systemic inflammation with
an impairment of HPV comparably to human sepsis. In
combination with perfusion of isolated lungs it permits
to study pulmonary vascular resistance under standard-
ized conditions and via double occlusion it also provides
information regarding the pulmonary microvasculature
[5, 15, 31, 32]. The dose of 50 ppm CO used in our
study was the most effective in prior dose–response ex-
periments with continuous CO application for 21 h in a
similar animal model by our group [30].
In the present study, we found a robust HPV in
healthy control mice with 100 % increase of pulmonary
vessel resistance during hypoxic ventilation (see Fig. 5a)
similar to other studies [15, 31, 35–37]. Due to LPS-
challenge, HPV was significantly diminished with a de-
creased pulmonary vessel resistance of 40 % comparably
to results in other experimental models [15, 31, 37]. We
here demonstrate for the first time, that HPV was pre-
served in isolated lungs of LPS-challenged mice after
exposure to 50 ppm CO for 18 h resulting in a HPV-
response of 90 %. HPV occurred due to an increase in
arterial resistance (see Fig. 6a and b), which is consistentwith previous studies using various animal models
[36, 38, 39]. The hypoxia induced increase in arterial
resistance was diminished after LPS-challenge, which
was prevented by CO inhalation. Thus, CO-dependent
preservation of HPV can be explained by preserved
arterial function without increase in venous pressure
or risk of pulmonary oedema.
The beneficial effects of continuously inhaled CO on
pulmonary vascular tone during endotoxemia in our
study are in line with previous studies, demonstrating
beneficial effects of CO in models of mechanically,
chemically or inflammatory induced acute lung injury
[17, 19, 40]. Additionally, protective effects of CO on
critically ill patients have become focus of intense clin-
ical research [22–24]. In septic patients with acute lung
injury, impairment of HPV leads to a decrease in arterial
oxygen saturation, which might be a contributing factor
to its high morbidity and mortality, underlining the clin-
ical need for treatment to prevent loss of HPV during
sepsis [1, 41, 42].
In a previous study, Mazzola et al. found an improved
respiratory function in LPS challenged pigs, pre-treated
with 250 ppm CO [14]. They reported ameliorations in
cytokine expression, respiratory compliance, airway re-
sistance and respiratory acidosis. Differently from our
study, CO inhalation was stopped before LPS application
and the protocol was terminated after 4 h. In addition,
the animals received a continuous infusion of Ringer
lactate to prevent extreme hypotension, which inter-
fered with the blood pressure measurements. These
factors may have contributed to the lack of evidence for a
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the investigation by Mazzola et al. [14]. In contrast, we
were able to demonstrate a CO-induced preservation of
HPV in endotoxemic lungs. As this is the main mechan-
ism for ventilation perfusion matching, this might also
have contributed to the reported improvement in respira-
tory function in the above mentioned study.
In our study, CO had no effect on baseline PAP in
LPS- or saline-treated animals (see Fig. 3). This might
seem conflicting with its direct vasodilating properties
via activation of soluble guanylate cyclase (sGC) [28].
The 4.4-fold activation of sGC by CO, however, is con-
siderably lower than the 130-fold activation by NO [43].
Accordingly, inhalation of 100 ppm exogenous CO did not
affect PAP in healty mongrel dogs during hypoxia even after
blockade nitric oxide synthase [44]. Attenuation of HPV by
CO in isolated lungs of healthy pigs and rats was reported
only at much higher inhaled concentrations in the range of
10 vol.% – equivalent to 100000 ppm [45, 46]. In addition it
has to be noted that we did not apply CO in our study
while ventilating the isolated perfused lungs.
Investigating the underlying molecular mechanism
behind the beneficial CO effects on HPV during endo-
toxemia, we found no general anti-inflammatory effects
of CO on elevated serum cytokine concentration after
LPS-challenge in contrast to other studies [21, 47] (see
Table 1). However, previously observed CO effects on
cytokine concentration are inconsistent and furthermore
appear to be dependent on the magnitude of the CO-
concentration. Otterbein et al. report a concentration
dependent decrease of pro-inflammatory serum cytokine
concentration in LPS-challenged mice exposed to 10-
500 ppm CO [27]. On the other hand, Ghosh et al. did
not find a decrease in TNF-α concentration after
500 ppm CO exposure in LPS-challenged mice [12]. We
used an even lower CO-concentration of 50 ppm, which
may explain the absence of an effect on systemic cyto-
kine concentration. Of interest, carboxy-Hb levels were
measured in our prior dose–response experiments after
more than 20 h of exposure to 50 ppm CO and varied
between 4-9 % COHb, which is in line with previous
studies [12, 17, 19, 30]. Thus, the observed preservation
of HPV after CO exposure seems independent of a
general anti-inflammatory effect of CO. However, it
must be noted that a local anti-inflammatory effect of CO
on cytokine expression in lung tissue cannot be excluded.
Accordingly, Goebel et al. found no systemic anti-
inflammatory effects with respect to cytokine expression
after exposure to 250 ppm CO, but they reported a de-
crease in TNF-α and IL-1β mRNA expression in lung tis-
sue of pigs with cardio-pulmonary bypass [18]. In the
present study, cytokine expression in lung tissue was not
determined and cytokine measurements were only per-
formed at the endpoint of the experiment at 18 h afterLPS injection. Therefore, CO dependent alterations in
local cytokine expression in lung tissue or alterations in
cytokine concentration during earlier time points of endo-
toxemia might also have contributed to preservation of
HPV after CO exposure and may be an interesting focus
of further studies on pulmonary inflammation.
In the present study, we also measured HO-1 and
HO-2 mRNA as a marker of endogenous CO production
and anti-inflammatory CO effects. According with previ-
ous findings, no changes in lung HO-2 mRNA, the con-
stitutively expressed enzyme for endogenous CO
production, were detected [48].
A change in HO-1 mRNA expression may be a sign of
local anti-inflammatory CO effects during acute lung
injury, which is supported by Clayton et al., who found
an increase of lung HO-1 protein after hyperoxic injury
in rats, which was reduced after CO exposure [49]. We
found a 7-fold increase of lung HO-1 mRNA after LPS-
challenge, confirming the up-regulation of HO-1 as part
of the anti-inflammatory response mechanism [27, 29, 47].
Interestingly, in our data, we did not find the before men-
tioned significant reduction in HO-1 after CO inhalation
in LPS treated animals. However, comparing controls and
LPS-treated animals after CO exposure, the before men-
tioned difference in HO-1 expression was also lost (see
Fig. 7b).
In our measurements of NOS-2 mRNA, we found
that CO significantly reduced the LPS-induced 54-
fold increase to an 8-fold increase, suggesting NOS-2
as an important molecular target of CO effects on
HPV (see Fig. 7a). Therefore, our findings confirm
the LPS-induced NOS-2 up-regulation as an import-
ant first step in endotoxemic impairment of HPV. It
is important to note that the endogenous NO release
at the time point of the measurement had no influ-
ence on the recorded HPV data. To specifically study
pulmonary vasoconstrictor response to hypoxia at
18 h after LPS-injection we added indomethacine and
L-NAME to the perfusate during isolated-perfused
lung experiments. This approach allowed us to quan-
tify HPV responsiveness independent of endogenous
thromboxane and NO production as described before
[15, 31, 32]. In a previous study we could show that
impaired HPV is not due to counteracting endogen-
ous NO production at 18 h after LPS-injection – i.e.
cannot be restored by perfusing mouse lungs with L-
NAME [15].
Our finding that the inhalation of 50 ppm CO reduced
NOS-2 mRNA expression is in agreement with the re-
sults of other studies investigating the effects of similar
CO doses. In IL-1beta stimulated hepatocytes from rats
250 ppm CO has been found to decrease NOS-2 protein
and the formation of its active dimer [50]. In a rat model
of LPS induced multiorgan failure 250 ppm CO prevented
Jahn et al. Respiratory Research  (2015) 16:119 Page 10 of 12the up-regulation of iNOS and NO in lung tissue [51]. In
a further investigation, 250 ppm CO inhibited LPS-
induced activation of the transcription factor NF-kappa ß,
a regulator of NOS-2 gene expression, in peritoneal
mouse macrophages [52].
One of our central findings in search of the mechanism
of protective CO effects on HPV was the identification of
a critical time frame for inhaled CO to restore HPV after
LPS challenge: CO exposure during the first 6 or the sec-
ond 3 h after LPS injection preserved HPV in our study
(HPV of 90 % or 86 %, respectively (see Fig. 5b)), whereas
no improvement of HPV was observed when CO was ad-
ministered during the last 12 h after LPS-challenge.
Hence, CO had to be present at the beginning of endotox-
emia in order to achieve a preserved HPV response.
Considering this precise time frame for beneficial actions
of CO, the preservation of HPV may be achieved by inhib-
ition of the pulmonary NOS-2 up-regulation and a conse-
quent reduction in pulmonary NO production during early
endotoxemia as NOS-2 deficient mice are protected from
loss of HPV during sepsis [15]. A peak concentration of
NOS-2 mRNA at 6 h following LPS challenge in mice with
a subsequent increase in NOS-2 activity at 12 h which was
reported by Salimuddin et al. is in agreement with the
time interval during which inhaled CO restored HPV in
our study [53]. Furthermore, previous studies demon-
strated that inhibition of NOS-2 and dependent NO pro-
duction must occur during an early phase of endotoxemia
to preserve HPV, whereas inhibition of NO production at
a later time point does not restore HPV [5, 15, 32]. Thus,
Ullrich et al. found a sustained HPV in LPS-challenged
mice, when NOS-2 dependent NO production was inhib-
ited three hours after LPS-injection, which was not estab-
lished by NOS-2 inhibition during measurement of HPV
at 22 h after LPS-challenge [5]. Of note, the LPS-induced
peak of NOS-2 expression around six hours after LPS-
challenge reported in various investigations coincides
with the period during which CO had to be administered
for preservation of HPV in our study [4, 13, 15, 54].
Taken together, our results are in line with previous
findings suggesting a) that an early LPS induced NOS-2
activity is responsible for an initial impairment of HPV
and b) that HPV is subsequently maintained by other
factors which have likely been produced or activated de-
pending on the increased NO concentrations. Previous
studies indicate a possible involvement of arginase which
is coinduced by LPS with NOS-2 in lung tissue of mice
and has been demonstrated to reach its concentration
peak at 24 h after LPS application [53]. Induction of
NOS-2 in murine macrophages has been found to in-
crease arginase activity by S-nitrosylation of cysytein res-
idues [55]. Furthermore, application of an aginase
inhibitor 22 h after LPS challenge has actually been re-
ported to restore HPV in mice [56].In conclusion, exposure to low-dose CO in a concen-
tration of 50 ppm prevents impairment of HPV in LPS-
challenged mice. Preservation of HPV was due to
sustained arterial function and independent of systemic
serum cytokine concentration. Interestingly, CO had to
be administered during the second 3 h of endotoxemia
to bear its protective properties, indicating a limited
time frame for protective CO effects. Preserved HPV
was associated with a reduction in NOS-2 mRNA after
LPS-challenge, suggesting an important key role of CO
in prevention of inflammatory up-regulation of NOS-2
and consequent NO production. Our data implicate
that application of low-dose CO might be considered as
a future option for the treatment of inflammatory lung
failure and the consequent hypoxemia.
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